You are absolutely correct about insulin glargine. LCI also has Numbrino, which lagged in distribution due to the pandemic's causing a delay in elective surgery but does offer an excellent revenue stream. The company has some "irons in the fire" for growth, but it comes down to controlling their costs and paying down debt and for that they are shedding some assets (manufacturing plant). They may conduct an R/S to stay on the NYSE, which would also give them the chance to raise capital. Still, Elite needs to find a new partner.
News 
Market Data 
Discover 
AI
